ID   PPOX_HUMAN              Reviewed;         477 AA.
AC   P50336; D3DVG0; Q5VTW8;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-1996, sequence version 1.
DT   10-MAY-2017, entry version 161.
DE   RecName: Full=Protoporphyrinogen oxidase;
DE            Short=PPO;
DE            EC=1.3.3.4;
GN   Name=PPOX;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND FUNCTION.
RC   TISSUE=Placenta;
RX   PubMed=7713909; DOI=10.1074/jbc.270.14.8076;
RA   Nishimura K., Taketani S., Inokuchi H.;
RT   "Cloning of a human cDNA for protoporphyrinogen oxidase by
RT   complementation in vivo of a hemG mutant of Escherichia coli.";
RL   J. Biol. Chem. 270:8076-8080(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Placenta;
RX   PubMed=8771201; DOI=10.1002/pro.5560050112;
RA   Dailey T.A., Dailey H.A.;
RT   "Human protoporphyrinogen oxidase: expression, purification, and
RT   characterization of the cloned enzyme.";
RL   Protein Sci. 5:98-105(1996).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT HIS-304.
RX   PubMed=8806618; DOI=10.1006/bbrc.1996.1337;
RA   Puy H., Robreau A.-M., Rosipal R., Nordmann Y., Deybach J.-C.;
RT   "Protoporphyrinogen oxidase: complete genomic sequence and
RT   polymorphisms in the human gene.";
RL   Biochem. Biophys. Res. Commun. 226:226-230(1996).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D.,
RA   Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A.,
RA   Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F.,
RA   McDonald L., Evans R., Phillips K., Atkinson A., Cooper R., Jones C.,
RA   Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G.,
RA   Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D.,
RA   Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G.,
RA   Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J.,
RA   Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R.,
RA   Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D.,
RA   Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G.,
RA   Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M.,
RA   Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J.,
RA   Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M.,
RA   Loveland J., Lovell J., Lush M.J., Lyne R., Martin S.,
RA   Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S.,
RA   Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C.,
RA   Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z.,
RA   Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E.,
RA   Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A.,
RA   Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R.,
RA   Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V.,
RA   Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [8]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M.,
RA   Ayoub D., Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [9]
RP   X-RAY CRYSTALLOGRAPHY (1.90 ANGSTROMS) IN COMPLEX WITH FAD AND
RP   ACIFLUORFEN, CATALYTIC ACTIVITY, FUNCTION, SUBUNIT, CHARACTERIZATION
RP   OF VARIANTS VP ASP-11; THR-12; PHE-15; PRO-20; PRO-38; ALA-40; GLU-40;
RP   TRP-59; PRO-73; GLY-84; PRO-85; PRO-106; PRO-138; ASP-139; VAL-143;
RP   CYS-152; PRO-154; MET-158; HIS-168; VAL-178; VAL-205; CYS-217;
RP   GLY-224; ARG-232; ASP-282; ASN-283; PRO-295; ARG-330; ALA-332;
RP   GLY-335; CYS-348; ALA-349; PRO-350; ARG-358; ASP-397; PHE-401;
RP   PRO-433; PRO-444; ARG-448; PRO-450 AND ARG-453, AND MUTAGENESIS OF
RP   LEU-74; ARG-97; LEU-166; GLY-169; SER-284; VAL-290; PHE-331; LEU-334;
RP   VAL-347 AND MET-368.
RX   PubMed=21048046; DOI=10.1096/fj.10-170811;
RA   Qin X., Tan Y., Wang L., Wang Z., Wang B., Wen X., Yang G., Xi Z.,
RA   Shen Y.;
RT   "Structural insight into human variegate porphyria disease.";
RL   FASEB J. 25:653-664(2011).
RN   [10]
RP   X-RAY CRYSTALLOGRAPHY (2.60 ANGSTROMS) OF MUTANTS GLY-59 AND GLN-59 IN
RP   COMPLEXES WITH FAD AND ACIFLUORFEN, FUNCTION, CATALYTIC ACTIVITY,
RP   MUTAGENESIS OF ARG-59; ARG-97; LEU-166; GLY-169; PHE-331; LEU-334;
RP   VAL-347 AND MET-368, AND CHARACTERIZATION OF VARIANTS VP TRP-59;
RP   HIS-168; ARG-330; GLY-335; ALA-349; PHE-401 AND ARG-453.
RX   PubMed=23467411; DOI=10.1074/jbc.M113.459768;
RA   Wang B., Wen X., Qin X., Wang Z., Tan Y., Shen Y., Xi Z.;
RT   "Quantitative structural insight into human variegate porphyria
RT   disease.";
RL   J. Biol. Chem. 288:11731-11740(2013).
RN   [11]
RP   VARIANT VP ARG-232, AND VARIANT HIS-304.
RX   PubMed=8852667; DOI=10.1093/hmg/5.3.407;
RA   Deybach J.-C., Puy H., Robreau A.-M., Lamoril J., da Silva V.,
RA   Grandchamp B., Nordmann Y.;
RT   "Mutations in the protoporphyrinogen oxidase gene in patients with
RT   variegate porphyria.";
RL   Hum. Mol. Genet. 5:407-410(1996).
RN   [12]
RP   VARIANTS VP PRO-20; TRP-59 AND CYS-168.
RX   PubMed=8817334; DOI=10.1093/hmg/5.7.981;
RA   Warnich L., Kotze M.J., Groenewald I.M., Groenewald J.Z.,
RA   van Brakel M.G., van Heerden C.J., de Villiers J.N., van de Ven W.J.,
RA   Schoenmakers E.F., Taketani S., Retief A.E.;
RT   "Identification of three mutations and associated haplotypes in the
RT   protoporphyrinogen oxidase gene in South African families with
RT   variegate porphyria.";
RL   Hum. Mol. Genet. 5:981-984(1996).
RN   [13]
RP   VARIANTS VP TRP-59 AND CYS-168.
RX   PubMed=8673113; DOI=10.1038/ng0596-95;
RA   Meissner P.N., Dailey T.A., Hift R.J., Ziman M., Corrigall A.V.,
RA   Roberts A.G., Meissner D.M., Kirsch R.E., Dailey H.A.;
RT   "A R59W mutation in human protoporphyrinogen oxidase results in
RT   decreased enzyme activity and is prevalent in South Africans with
RT   variegate porphyria.";
RL   Nat. Genet. 13:95-97(1996).
RN   [14]
RP   VARIANT VP CYS-152.
RX   PubMed=9763307; DOI=10.1007/s004030050333;
RA   Frank J., Poh-Fitzpatrick M.B., King L.E. Jr., Christiano A.M.;
RT   "The genetic basis of 'Scarsdale Gourmet Diet' variegate porphyria: a
RT   missense mutation in the protoporphyrinogen oxidase gene.";
RL   Arch. Dermatol. Res. 290:441-445(1998).
RN   [15]
RP   VARIANT VP PRO-450.
RX   PubMed=9541112; DOI=10.1136/jmg.35.3.244;
RA   Frank J., Lam H., Zaider E., Poh-Fitzpatrick M., Christiano A.M.;
RT   "Molecular basis of variegate porphyria: a missense mutation in the
RT   protoporphyrinogen oxidase gene.";
RL   J. Med. Genet. 35:244-247(1998).
RN   [16]
RP   VARIANTS VP GLU-169; ALA-349; ARG-358 AND PRO-433, AND
RP   CHARACTERIZATION OF VARIANTS VP GLU-169; ALA-349; ARG-358 AND PRO-433.
RX   PubMed=9811936; DOI=10.1093/hmg/7.12.1921;
RA   Roberts A.G., Puy H., Dailey T.A., Morgan R.R., Whatley S.D.,
RA   Dailey H.A., Martasek P., Nordmann Y., Deybach J.C., Elder G.H.;
RT   "Molecular characterization of homozygous variegate porphyria.";
RL   Hum. Mol. Genet. 7:1921-1925(1998).
RN   [17]
RP   VARIANTS ARG-256 AND HIS-304, AND VARIANTS VP PRO-38; GLU-40; PRO-73;
RP   GLY-84; PRO-85; VAL-143; CYS-152; PRO-154; MET-158; HIS-168; VAL-172;
RP   ARG-232; HIS-281 DEL; ASP-282; PRO-295; GLY-335; PRO-350; PRO-444;
RP   ARG-453 AND VAL-453.
RX   PubMed=10486317; DOI=10.1086/302586;
RA   Whatley S.D., Puy H., Morgan R.R., Robreau A.M., Roberts A.G.,
RA   Nordmann Y., Elder G.H., Deybach J.C.;
RT   "Variegate porphyria in Western Europe: identification of PPOX gene
RT   mutations in 104 families, extent of allelic heterogeneity, and
RT   absence of correlation between phenotype and type of mutation.";
RL   Am. J. Hum. Genet. 65:984-994(1999).
RN   [18]
RP   VARIANT VP ARG-448.
RX   PubMed=11074242; DOI=10.1016/S0009-9120(00)00142-9;
RA   Maeda N., Horie Y., Sasaki Y., Adachi K., Nanba E., Nishida K.,
RA   Saigo R., Nakagawa M., Kawasaki H., Kudo Y., Kondo M.;
RT   "Three novel mutations in the protoporphyrinogen oxidase gene in
RT   Japanese patients with variegate porphyria.";
RL   Clin. Biochem. 33:495-500(2000).
RN   [19]
RP   VARIANTS VP PRO-106 AND VAL-178.
RX   PubMed=11102990;
RX   DOI=10.1002/1098-1004(200012)16:6<532::AID-HUMU18>3.3.CO;2-J;
RA   De Siervi A., Parera V.E., del C Batlle A.M., Rossetti M.V.;
RT   "Two new mutations (H106P and L178V) in the protoporphyrinogen oxidase
RT   gene in Argentinean patients with variegate porphyria.";
RL   Hum. Mutat. 16:532-532(2000).
RN   [20]
RP   VARIANTS VP TRP-59; PRO-138 AND CYS-348.
RX   PubMed=10870850; DOI=10.1006/mgme.2000.2975;
RA   Corrigall A.V., Hift R.J., Davids L.M., Hancock V., Meissner D.,
RA   Kirsch R.E., Meissner P.N.;
RT   "Homozygous variegate porphyria in South Africa: genotypic analysis in
RT   two cases.";
RL   Mol. Genet. Metab. 69:323-330(2000).
RN   [21]
RP   VARIANT VP THR-12, VARIANT ARG-256, CHARACTERIZATION OF VARIANT VP
RP   THR-12, AND CHARACTERIZATION OF VARIANT ARG-256.
RX   PubMed=11286631; DOI=10.1046/j.1523-1747.2001.01293.x;
RA   Kauppinen R., Timonen K., von und zu Fraunberg M., Laitinen E.,
RA   Ahola H., Tenhunen R., Taketani S., Mustajoki P.;
RT   "Homozygous variegate porphyria: 20 y follow-up and characterization
RT   of molecular defect.";
RL   J. Invest. Dermatol. 116:610-613(2001).
RN   [22]
RP   VARIANT VP SER-11.
RX   PubMed=11348478; DOI=10.1046/j.1523-1747.2001.01308.x;
RA   Frank J., Jugert F.K., Merk H.F., Kalka K., Goerz G., Anderson K.,
RA   Bickers D.R., Poh-Fitzpatrick M.B., Christiano A.M.;
RT   "A spectrum of novel mutations in the protoporphyrinogen oxidase gene
RT   in 13 families with variegate porphyria.";
RL   J. Invest. Dermatol. 116:821-823(2001).
RN   [23]
RP   VARIANTS VP PHE-15 AND MET-290.
RX   PubMed=11350188; DOI=10.1006/mgme.2001.3163;
RA   Corrigall A.V., Hift R.J., Davids L.M., Hancock V., Meissner D.,
RA   Kirsch R.E., Meissner P.N.;
RT   "Identification of the first variegate porphyria mutation in an
RT   indigenous black South African and further evidence for heterogeneity
RT   in variegate porphyria.";
RL   Mol. Genet. Metab. 73:91-96(2001).
RN   [24]
RP   VARIANTS VP CYS-152 AND PHE-401, AND CHARACTERIZATION OF VARIANT VP
RP   CYS-152.
RX   PubMed=11474578;
RA   von und zu Fraunberg M., Tenhunen R., Kauppinen R.;
RT   "Expression and characterization of six mutations in the
RT   protoporphyrinogen oxidase gene among Finnish variegate porphyria
RT   patients.";
RL   Mol. Med. 7:320-328(2001).
RN   [25]
RP   VARIANTS VP TRP-59; CYS-217 AND SER-236.
RX   PubMed=12380696; DOI=10.1046/j.1445-5994.2002.00274.x;
RA   Rossi E., Chin C.Y., Beilby J.P., Waso H.F., Warnich L.;
RT   "Variegate porphyria in Western Australian Aboriginal patients.";
RL   Intern. Med. J. 32:445-450(2002).
RN   [26]
RP   CHARACTERIZATION OF VARIANTS VP PRO-20; TRP-59; CYS-168 AND CYS-348.
RX   PubMed=12922165; DOI=10.1016/S1570-9639(03)00186-9;
RA   Maneli M.H., Corrigall A.V., Klump H.H., Davids L.M., Kirsch R.E.,
RA   Meissner P.N.;
RT   "Kinetic and physical characterisation of recombinant wild-type and
RT   mutant human protoporphyrinogen oxidases.";
RL   Biochim. Biophys. Acta 1650:10-21(2003).
RN   [27]
RP   VARIANTS VP CYS-152; LEU-158; VAL-205 AND ARG-330.
RX   PubMed=12859407; DOI=10.1034/j.1399-0004.2003.00116.x;
RA   Wiman A., Harper P., Floderus Y.;
RT   "Nine novel mutations in the protoporphyrinogen oxidase gene in
RT   Swedish families with variegate porphyria.";
RL   Clin. Genet. 64:122-130(2003).
RN   [28]
RP   VARIANT VP ASN-283.
RX   PubMed=12655566; DOI=10.1002/humu.9125;
RA   D'Amato M., Bonuglia M., Barile S., Griso D., Macri A., Biolcati G.;
RT   "Genetic analysis of variegate porphyria (VP) in Italy: identification
RT   of six novel mutations in the protoporphyrinogen oxidase (PPOX)
RT   gene.";
RL   Hum. Mutat. 21:448-448(2003).
RN   [29]
RP   VARIANT VP ALA-40.
RX   PubMed=14669009; DOI=10.1007/s00439-003-1059-5;
RA   Gouya L., Puy H., Robreau A.-M., Lyoumi S., Lamoril J., Da Silva V.,
RA   Grandchamp B., Deybach J.-C.;
RT   "Modulation of penetrance by the wild-type allele in dominantly
RT   inherited erythropoietic protoporphyria and acute hepatic
RT   porphyrias.";
RL   Hum. Genet. 114:256-262(2004).
RN   [30]
RP   VARIANT VP SER-232.
RX   PubMed=16433813; DOI=10.1111/j.1365-2133.2005.06978.x;
RA   Poblete-Gutierrez P., Wolff C., Farias R., Frank J.;
RT   "A Chilean boy with severe photosensitivity and finger shortening: the
RT   first case of homozygous variegate porphyria in South America.";
RL   Br. J. Dermatol. 154:368-371(2006).
RN   [31]
RP   CHARACTERIZATION OF VARIANTS VP PRO-20; TRP-59 AND CYS-168.
RX   PubMed=16621625; DOI=10.1016/j.cellbi.2006.02.001;
RA   Davids L.M., Corrigall A.V., Meissner P.N.;
RT   "Mitochondrial targeting of human protoporphyrinogen oxidase.";
RL   Cell Biol. Int. 30:416-426(2006).
RN   [32]
RP   VARIANT VP ARG-224.
RX   PubMed=16922948; DOI=10.1111/j.1468-3083.2006.01705.x;
RA   Lecha M., Badenas C., Puig S., Orfila J., Mila M., To-Figueras J.,
RA   Munoz C., Mercader P., Herrero C.;
RT   "Genetic studies in variegate porphyria in Spain. Identification of
RT   gene mutations and family study for carrier detection.";
RL   J. Eur. Acad. Dermatol. Venereol. 20:974-979(2006).
RN   [33]
RP   VARIANT VP ASP-11.
RX   PubMed=16947091;
RA   Schneider-Yin X., Minder E.I.;
RT   "Swiss patients with variegate porphyria have unique mutations.";
RL   Swiss. Med. Wkly. 136:515-519(2006).
RN   [34]
RP   VARIANT VP ASP-139.
RX   PubMed=18350656;
RA   Ausenda S., Di Pierro E., Brancaleoni V., Besana V., Cappellini M.D.;
RT   "Novel human pathological mutations. Gene symbol: PPOX. Disease:
RT   porphyria, variegate.";
RL   Hum. Genet. 122:417-417(2007).
RN   [35]
RP   VARIANTS VP VAL-34; GLY-224 AND ALA-332.
RX   PubMed=18570668; DOI=10.1186/1471-2350-9-54;
RA   Rossetti M.V., Granata B.X., Giudice J., Parera V.E., Batlle A.;
RT   "Genetic and biochemical studies in Argentinean patients with
RT   variegate porphyria.";
RL   BMC Med. Genet. 9:54-54(2008).
RN   [36]
RP   VARIANT VP ASP-397.
RX   PubMed=19320019;
RA   Ausenda S., Moriondo V., Marchini S., Besana V., Di Pierro E.,
RA   Brancaleoni V., Ventura P., Rocchi E., Cappellini M.D.;
RT   "Novel human pathological mutations. Gene symbol: PPOX. Disease:
RT   porphyria, variegate.";
RL   Hum. Genet. 125:344-344(2009).
RN   [37]
RP   VARIANTS VP VAL-34; PHE-76; GLY-224; ALA-332 AND CYS-422, AND
RP   CHARACTERIZATION OF VARIANTS VP VAL-34; PHE-76; GLY-224; ALA-332 AND
RP   CYS-422.
RX   PubMed=23430901; DOI=10.1007/8904_2011_77;
RA   Mendez M., Granata B.X., Jimenez M.J., Parera V.E., Batlle A.,
RA   de Salamanca R.E., Rossetti M.V.;
RT   "Functional characterization of five protoporphyrinogen oxidase
RT   missense mutations found in Argentinean variegate porphyria
RT   patients.";
RL   JIMD Rep. 4:91-97(2012).
RN   [38]
RP   VARIANTS VP ARG-57 AND ARG-420.
RX   PubMed=24073655; DOI=10.1111/ced.12071;
RA   Pinder V.A., Holden S.T., Deshpande C., Siddiqui A., Mellerio J.E.,
RA   Wraige E., Powell A.M.;
RT   "Homozygous variegate porphyria presenting with developmental and
RT   language delay in childhood.";
RL   Clin. Exp. Dermatol. 38:737-740(2013).
CC   -!- FUNCTION: Catalyzes the 6-electron oxidation of
CC       protoporphyrinogen-IX to form protoporphyrin-IX.
CC       {ECO:0000269|PubMed:21048046, ECO:0000269|PubMed:23467411,
CC       ECO:0000269|PubMed:7713909}.
CC   -!- CATALYTIC ACTIVITY: Protoporphyrinogen-IX + 3 O(2) =
CC       protoporphyrin-IX + 3 H(2)O(2). {ECO:0000269|PubMed:21048046,
CC       ECO:0000269|PubMed:23467411}.
CC   -!- COFACTOR:
CC       Name=FAD; Xref=ChEBI:CHEBI:57692;
CC       Note=Binds 1 FAD per subunit.;
CC   -!- PATHWAY: Porphyrin-containing compound metabolism; protoporphyrin-
CC       IX biosynthesis; protoporphyrin-IX from protoporphyrinogen-IX:
CC       step 1/1.
CC   -!- SUBUNIT: Monomer. Homodimer. {ECO:0000269|PubMed:21048046}.
CC   -!- SUBCELLULAR LOCATION: Mitochondrion inner membrane {ECO:0000250};
CC       Peripheral membrane protein {ECO:0000250}; Intermembrane side
CC       {ECO:0000250}.
CC   -!- TISSUE SPECIFICITY: Expressed in heart, brain, placenta, lung,
CC       liver, skeletal muscle, kidney and pancreas.
CC   -!- DISEASE: Variegate porphyria (VP) [MIM:176200]: A form of
CC       porphyria. Porphyrias are inherited defects in the biosynthesis of
CC       heme, resulting in the accumulation and increased excretion of
CC       porphyrins or porphyrin precursors. They are classified as
CC       erythropoietic or hepatic, depending on whether the enzyme
CC       deficiency occurs in red blood cells or in the liver. Variegate
CC       porphyria is the most common form of porphyria in South Africa. It
CC       is characterized by skin hyperpigmentation and hypertrichosis,
CC       abdominal pain, tachycardia, hypertension and neuromuscular
CC       disturbances. High fecal levels of protoporphyrin and
CC       coproporphyrin, increased urine uroporphyrins and iron overload
CC       are typical markers of the disease. {ECO:0000269|PubMed:10486317,
CC       ECO:0000269|PubMed:10870850, ECO:0000269|PubMed:11074242,
CC       ECO:0000269|PubMed:11102990, ECO:0000269|PubMed:11286631,
CC       ECO:0000269|PubMed:11348478, ECO:0000269|PubMed:11350188,
CC       ECO:0000269|PubMed:11474578, ECO:0000269|PubMed:12380696,
CC       ECO:0000269|PubMed:12655566, ECO:0000269|PubMed:12859407,
CC       ECO:0000269|PubMed:12922165, ECO:0000269|PubMed:14669009,
CC       ECO:0000269|PubMed:16433813, ECO:0000269|PubMed:16621625,
CC       ECO:0000269|PubMed:16922948, ECO:0000269|PubMed:16947091,
CC       ECO:0000269|PubMed:18350656, ECO:0000269|PubMed:18570668,
CC       ECO:0000269|PubMed:19320019, ECO:0000269|PubMed:21048046,
CC       ECO:0000269|PubMed:23430901, ECO:0000269|PubMed:23467411,
CC       ECO:0000269|PubMed:24073655, ECO:0000269|PubMed:8673113,
CC       ECO:0000269|PubMed:8817334, ECO:0000269|PubMed:8852667,
CC       ECO:0000269|PubMed:9541112, ECO:0000269|PubMed:9763307,
CC       ECO:0000269|PubMed:9811936}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry. Mutations
CC       leading to severe PPOX deficiency cause the rare homozygous
CC       variant form of VP. Missense mutations that preserve 10%-25% of
CC       wild-type activity may not cause clinically overt VP in
CC       heterozygotes (PubMed:9811936). Mutations with intermediate effect
CC       on catalytic activity may cause VP, but with a low clinical
CC       penetrance (PubMed:10486317). {ECO:0000269|PubMed:10486317,
CC       ECO:0000269|PubMed:9811936}.
CC   -!- SIMILARITY: Belongs to the protoporphyrinogen oxidase family.
CC       {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Protoporphyrinogen oxidase
CC       entry;
CC       URL="https://en.wikipedia.org/wiki/Protoporphyrinogen_oxidase";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; D38537; BAA07538.1; -; mRNA.
DR   EMBL; U26446; AAA67690.1; -; mRNA.
DR   EMBL; X99450; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL590714; CAH72144.1; -; Genomic_DNA.
DR   EMBL; CH471121; EAW52636.1; -; Genomic_DNA.
DR   EMBL; CH471121; EAW52639.1; -; Genomic_DNA.
DR   EMBL; CH471121; EAW52641.1; -; Genomic_DNA.
DR   EMBL; BC002357; AAH02357.1; -; mRNA.
DR   CCDS; CCDS1221.1; -.
DR   PIR; JC4971; A56449.
DR   RefSeq; NP_000300.1; NM_000309.3.
DR   RefSeq; NP_001116236.1; NM_001122764.1.
DR   UniGene; Hs.517373; -.
DR   PDB; 3NKS; X-ray; 1.90 A; A=1-477.
DR   PDB; 4IVM; X-ray; 2.77 A; B=1-477.
DR   PDB; 4IVO; X-ray; 2.60 A; B=1-477.
DR   PDBsum; 3NKS; -.
DR   PDBsum; 4IVM; -.
DR   PDBsum; 4IVO; -.
DR   ProteinModelPortal; P50336; -.
DR   SMR; P50336; -.
DR   BioGrid; 111492; 20.
DR   IntAct; P50336; 20.
DR   MINT; MINT-1402949; -.
DR   STRING; 9606.ENSP00000343943; -.
DR   BindingDB; P50336; -.
DR   ChEMBL; CHEMBL1926488; -.
DR   iPTMnet; P50336; -.
DR   PhosphoSitePlus; P50336; -.
DR   SwissPalm; P50336; -.
DR   BioMuta; PPOX; -.
DR   DMDM; 1709742; -.
DR   EPD; P50336; -.
DR   MaxQB; P50336; -.
DR   PaxDb; P50336; -.
DR   PeptideAtlas; P50336; -.
DR   PRIDE; P50336; -.
DR   Ensembl; ENST00000352210; ENSP00000343943; ENSG00000143224.
DR   Ensembl; ENST00000367999; ENSP00000356978; ENSG00000143224.
DR   GeneID; 5498; -.
DR   KEGG; hsa:5498; -.
DR   UCSC; uc001fyg.3; human.
DR   CTD; 5498; -.
DR   DisGeNET; 5498; -.
DR   GeneCards; PPOX; -.
DR   GeneReviews; PPOX; -.
DR   HGNC; HGNC:9280; PPOX.
DR   HPA; HPA030123; -.
DR   MalaCards; PPOX; -.
DR   MIM; 176200; phenotype.
DR   MIM; 600923; gene.
DR   neXtProt; NX_P50336; -.
DR   OpenTargets; ENSG00000143224; -.
DR   Orphanet; 79473; Porphyria variegata.
DR   PharmGKB; PA33608; -.
DR   eggNOG; KOG1276; Eukaryota.
DR   eggNOG; COG1232; LUCA.
DR   GeneTree; ENSGT00390000008744; -.
DR   HOGENOM; HOG000269479; -.
DR   HOVERGEN; HBG001709; -.
DR   InParanoid; P50336; -.
DR   KO; K00231; -.
DR   OMA; DSCCFDM; -.
DR   OrthoDB; EOG091G08PW; -.
DR   PhylomeDB; P50336; -.
DR   TreeFam; TF323479; -.
DR   BioCyc; MetaCyc:HS07011-MONOMER; -.
DR   BRENDA; 1.3.3.4; 2681.
DR   Reactome; R-HSA-189451; Heme biosynthesis.
DR   SABIO-RK; P50336; -.
DR   UniPathway; UPA00251; UER00324.
DR   ChiTaRS; PPOX; human.
DR   GeneWiki; PPOX; -.
DR   GenomeRNAi; 5498; -.
DR   PRO; PR:P50336; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   Bgee; ENSG00000143224; -.
DR   CleanEx; HS_PPOX; -.
DR   ExpressionAtlas; P50336; baseline and differential.
DR   Genevisible; P50336; HS.
DR   GO; GO:0031305; C:integral component of mitochondrial inner membrane; IEA:Ensembl.
DR   GO; GO:0031304; C:intrinsic component of mitochondrial inner membrane; ISS:UniProtKB.
DR   GO; GO:0005758; C:mitochondrial intermembrane space; TAS:Reactome.
DR   GO; GO:0031966; C:mitochondrial membrane; IMP:UniProtKB.
DR   GO; GO:0050660; F:flavin adenine dinucleotide binding; TAS:UniProtKB.
DR   GO; GO:0004729; F:oxygen-dependent protoporphyrinogen oxidase activity; IDA:UniProtKB.
DR   GO; GO:0006783; P:heme biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0055114; P:oxidation-reduction process; IDA:UniProtKB.
DR   GO; GO:0006779; P:porphyrin-containing compound biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0006782; P:protoporphyrinogen IX biosynthetic process; IEA:UniProtKB-UniPathway.
DR   GO; GO:0042493; P:response to drug; IEA:Ensembl.
DR   Gene3D; 3.50.50.60; -; 1.
DR   InterPro; IPR002937; Amino_oxidase.
DR   InterPro; IPR023753; FAD/NAD-binding_dom.
DR   InterPro; IPR004572; Protoporphyrinogen_oxidase.
DR   Pfam; PF01593; Amino_oxidase; 1.
DR   SUPFAM; SSF51905; SSF51905; 2.
DR   TIGRFAMs; TIGR00562; proto_IX_ox; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Complete proteome; Disease mutation; FAD; Flavoprotein;
KW   Heme biosynthesis; Membrane; Mitochondrion;
KW   Mitochondrion inner membrane; Oxidoreductase; Polymorphism;
KW   Porphyrin biosynthesis; Reference proteome.
FT   CHAIN         1    477       Protoporphyrinogen oxidase.
FT                                /FTId=PRO_0000135270.
FT   NP_BIND       9     14       FAD. {ECO:0000269|PubMed:21048046}.
FT   NP_BIND      34     35       FAD. {ECO:0000269|PubMed:21048046}.
FT   NP_BIND      57     60       FAD. {ECO:0000269|PubMed:21048046}.
FT   NP_BIND     454    456       FAD. {ECO:0000269|PubMed:21048046}.
FT   BINDING      42     42       FAD; via amide nitrogen.
FT                                {ECO:0000269|PubMed:21048046}.
FT   BINDING     257    257       FAD; via amide nitrogen and carbonyl
FT                                oxygen. {ECO:0000269|PubMed:21048046}.
FT   BINDING     449    449       FAD; via amide nitrogen.
FT                                {ECO:0000269|PubMed:21048046}.
FT   VARIANT      11     11       G -> D (in VP; abolishes enzyme activity;
FT                                impairs protein folding and/or
FT                                stability). {ECO:0000269|PubMed:16947091,
FT                                ECO:0000269|PubMed:21048046}.
FT                                /FTId=VAR_070378.
FT   VARIANT      11     11       G -> S (in VP).
FT                                {ECO:0000269|PubMed:11348478}.
FT                                /FTId=VAR_070377.
FT   VARIANT      12     12       I -> T (in VP; strongly decreases enzyme
FT                                activity; impairs protein folding and/or
FT                                stability; dbSNP:rs28936677).
FT                                {ECO:0000269|PubMed:11286631,
FT                                ECO:0000269|PubMed:21048046}.
FT                                /FTId=VAR_070379.
FT   VARIANT      15     15       L -> F (in VP; strongly decreases enzyme
FT                                activity; impairs protein folding and/or
FT                                stability; dbSNP:rs769452432).
FT                                {ECO:0000269|PubMed:11350188,
FT                                ECO:0000269|PubMed:21048046}.
FT                                /FTId=VAR_070380.
FT   VARIANT      20     20       H -> P (in VP; strongly decreases enzyme
FT                                activity; more resistant to thermal
FT                                denaturation than wild-type enzyme;
FT                                abolishes mitochondrial protein targeting
FT                                and localization; dbSNP:rs121918326).
FT                                {ECO:0000269|PubMed:12922165,
FT                                ECO:0000269|PubMed:16621625,
FT                                ECO:0000269|PubMed:21048046,
FT                                ECO:0000269|PubMed:8817334}.
FT                                /FTId=VAR_070381.
FT   VARIANT      34     34       E -> V (in VP; decreases enzyme
FT                                activity). {ECO:0000269|PubMed:18570668,
FT                                ECO:0000269|PubMed:23430901}.
FT                                /FTId=VAR_070382.
FT   VARIANT      38     38       R -> P (in VP; strongly decreases enzyme
FT                                activity; impairs protein folding and/or
FT                                stability). {ECO:0000269|PubMed:10486317,
FT                                ECO:0000269|PubMed:21048046}.
FT                                /FTId=VAR_070383.
FT   VARIANT      40     40       G -> A (in VP; strongly decreases enzyme
FT                                activity; impairs protein folding and/or
FT                                stability). {ECO:0000269|PubMed:14669009,
FT                                ECO:0000269|PubMed:21048046}.
FT                                /FTId=VAR_070384.
FT   VARIANT      40     40       G -> E (in VP; abolishes enzyme activity;
FT                                impairs protein folding and/or
FT                                stability). {ECO:0000269|PubMed:10486317,
FT                                ECO:0000269|PubMed:21048046}.
FT                                /FTId=VAR_070385.
FT   VARIANT      57     57       G -> R (in VP; dbSNP:rs764352037).
FT                                {ECO:0000269|PubMed:24073655}.
FT                                /FTId=VAR_070386.
FT   VARIANT      59     59       R -> W (in VP; strongly decreases enzyme
FT                                activity; does not affect mitochondrial
FT                                protein targeting and localization; more
FT                                resistant to thermal denaturation than
FT                                wild-type enzyme; dbSNP:rs121918324).
FT                                {ECO:0000269|PubMed:10870850,
FT                                ECO:0000269|PubMed:12380696,
FT                                ECO:0000269|PubMed:12922165,
FT                                ECO:0000269|PubMed:16621625,
FT                                ECO:0000269|PubMed:21048046,
FT                                ECO:0000269|PubMed:23467411,
FT                                ECO:0000269|PubMed:8673113,
FT                                ECO:0000269|PubMed:8817334}.
FT                                /FTId=VAR_003686.
FT   VARIANT      73     73       L -> P (in VP; strongly decreases enzyme
FT                                activity; impairs protein folding and/or
FT                                stability). {ECO:0000269|PubMed:10486317,
FT                                ECO:0000269|PubMed:21048046}.
FT                                /FTId=VAR_070387.
FT   VARIANT      76     76       S -> F (in VP; decreases enzyme
FT                                activity). {ECO:0000269|PubMed:23430901}.
FT                                /FTId=VAR_070388.
FT   VARIANT      84     84       V -> G (in VP; strongly decreases enzyme
FT                                activity; impairs protein folding and/or
FT                                stability). {ECO:0000269|PubMed:10486317,
FT                                ECO:0000269|PubMed:21048046}.
FT                                /FTId=VAR_070389.
FT   VARIANT      85     85       L -> P (in VP; abolishes enzyme activity;
FT                                impairs protein folding and/or
FT                                stability). {ECO:0000269|PubMed:10486317,
FT                                ECO:0000269|PubMed:21048046}.
FT                                /FTId=VAR_070390.
FT   VARIANT     106    106       H -> P (in VP; strongly decreases enzyme
FT                                activity;). {ECO:0000269|PubMed:11102990,
FT                                ECO:0000269|PubMed:21048046}.
FT                                /FTId=VAR_070391.
FT   VARIANT     138    138       R -> P (in VP; slightly decreases enzyme
FT                                activity; dbSNP:rs767419411).
FT                                {ECO:0000269|PubMed:10870850,
FT                                ECO:0000269|PubMed:21048046}.
FT                                /FTId=VAR_070392.
FT   VARIANT     139    139       G -> D (in VP; strongly decreases enzyme
FT                                activity; dbSNP:rs369381477).
FT                                {ECO:0000269|PubMed:18350656,
FT                                ECO:0000269|PubMed:21048046}.
FT                                /FTId=VAR_070393.
FT   VARIANT     143    143       D -> V (in VP; strongly decreases enzyme
FT                                activity). {ECO:0000269|PubMed:10486317,
FT                                ECO:0000269|PubMed:21048046}.
FT                                /FTId=VAR_070394.
FT   VARIANT     152    152       R -> C (in VP; strongly decreases enzyme
FT                                activity). {ECO:0000269|PubMed:10486317,
FT                                ECO:0000269|PubMed:11474578,
FT                                ECO:0000269|PubMed:12859407,
FT                                ECO:0000269|PubMed:21048046,
FT                                ECO:0000269|PubMed:9763307}.
FT                                /FTId=VAR_003687.
FT   VARIANT     154    154       L -> P (in VP; strongly decreases enzyme
FT                                activity). {ECO:0000269|PubMed:10486317,
FT                                ECO:0000269|PubMed:21048046}.
FT                                /FTId=VAR_070395.
FT   VARIANT     158    158       V -> L (in VP).
FT                                {ECO:0000269|PubMed:12859407}.
FT                                /FTId=VAR_070396.
FT   VARIANT     158    158       V -> M (in VP; strongly decreases enzyme
FT                                activity). {ECO:0000269|PubMed:10486317,
FT                                ECO:0000269|PubMed:21048046}.
FT                                /FTId=VAR_070397.
FT   VARIANT     168    168       R -> C (in VP; strongly decreases enzyme
FT                                activity; does not affect mitochondrial
FT                                protein targeting and localization;
FT                                dbSNP:rs121918325).
FT                                {ECO:0000269|PubMed:12922165,
FT                                ECO:0000269|PubMed:16621625,
FT                                ECO:0000269|PubMed:8673113,
FT                                ECO:0000269|PubMed:8817334}.
FT                                /FTId=VAR_003688.
FT   VARIANT     168    168       R -> H (in VP; strongly decreases enzyme
FT                                activity; dbSNP:rs41270025).
FT                                {ECO:0000269|PubMed:10486317,
FT                                ECO:0000269|PubMed:21048046,
FT                                ECO:0000269|PubMed:23467411}.
FT                                /FTId=VAR_070398.
FT   VARIANT     169    169       G -> E (in VP; strongly decreases enzyme
FT                                activity). {ECO:0000269|PubMed:9811936}.
FT                                /FTId=VAR_070399.
FT   VARIANT     172    172       A -> V (in VP).
FT                                {ECO:0000269|PubMed:10486317}.
FT                                /FTId=VAR_070400.
FT   VARIANT     178    178       L -> V (in VP; strongly decreases enzyme
FT                                activity; dbSNP:rs757473753).
FT                                {ECO:0000269|PubMed:11102990,
FT                                ECO:0000269|PubMed:21048046}.
FT                                /FTId=VAR_070401.
FT   VARIANT     205    205       A -> V (in VP; no effect on enzyme
FT                                activity). {ECO:0000269|PubMed:12859407,
FT                                ECO:0000269|PubMed:21048046}.
FT                                /FTId=VAR_070402.
FT   VARIANT     217    217       R -> C (in VP; decreases enzyme activity;
FT                                impairs protein folding and/or stability;
FT                                dbSNP:rs751599052).
FT                                {ECO:0000269|PubMed:12380696,
FT                                ECO:0000269|PubMed:21048046}.
FT                                /FTId=VAR_070403.
FT   VARIANT     224    224       W -> G (in VP; abolishes enzyme activity;
FT                                impairs protein folding and/or
FT                                stability). {ECO:0000269|PubMed:18570668,
FT                                ECO:0000269|PubMed:21048046,
FT                                ECO:0000269|PubMed:23430901}.
FT                                /FTId=VAR_070404.
FT   VARIANT     224    224       W -> R (in VP).
FT                                {ECO:0000269|PubMed:16922948}.
FT                                /FTId=VAR_070405.
FT   VARIANT     232    232       G -> R (in VP; strongly decreases enzyme
FT                                activity; impairs protein folding and/or
FT                                stability; dbSNP:rs121918323).
FT                                {ECO:0000269|PubMed:10486317,
FT                                ECO:0000269|PubMed:21048046,
FT                                ECO:0000269|PubMed:8852667}.
FT                                /FTId=VAR_003689.
FT   VARIANT     232    232       G -> S (in VP).
FT                                {ECO:0000269|PubMed:16433813}.
FT                                /FTId=VAR_070406.
FT   VARIANT     236    236       L -> S (in VP).
FT                                {ECO:0000269|PubMed:12380696}.
FT                                /FTId=VAR_070407.
FT   VARIANT     256    256       P -> R (found in patients with the
FT                                homozygous variant of variegate
FT                                porphyria; unknown pathological
FT                                significance; reported as a polymorphism
FT                                in some Western European populations; the
FT                                variant results in reduction of activity
FT                                in a prokariotyc expression system but
FT                                has normal activity when expressed in an
FT                                eukaryotic system; dbSNP:rs12735723).
FT                                {ECO:0000269|PubMed:10486317,
FT                                ECO:0000269|PubMed:11286631}.
FT                                /FTId=VAR_034395.
FT   VARIANT     281    281       Missing (in VP).
FT                                {ECO:0000269|PubMed:10486317}.
FT                                /FTId=VAR_070408.
FT   VARIANT     282    282       V -> D (in VP; strongly decreases enzyme
FT                                activity; impairs protein folding and/or
FT                                stability). {ECO:0000269|PubMed:10486317,
FT                                ECO:0000269|PubMed:21048046}.
FT                                /FTId=VAR_070409.
FT   VARIANT     283    283       I -> N (in VP; strongly decreases enzyme
FT                                activity; impairs protein folding and/or
FT                                stability). {ECO:0000269|PubMed:12655566,
FT                                ECO:0000269|PubMed:21048046}.
FT                                /FTId=VAR_070410.
FT   VARIANT     290    290       V -> M (in VP).
FT                                {ECO:0000269|PubMed:11350188}.
FT                                /FTId=VAR_070411.
FT   VARIANT     295    295       L -> P (in VP; strongly decreases enzyme
FT                                activity; impairs protein folding and/or
FT                                stability). {ECO:0000269|PubMed:10486317,
FT                                ECO:0000269|PubMed:21048046}.
FT                                /FTId=VAR_070412.
FT   VARIANT     304    304       R -> H (in dbSNP:rs36013429).
FT                                {ECO:0000269|PubMed:10486317,
FT                                ECO:0000269|PubMed:8806618,
FT                                ECO:0000269|PubMed:8852667}.
FT                                /FTId=VAR_003690.
FT   VARIANT     330    330       G -> R (in VP; strongly decreases enzyme
FT                                activity). {ECO:0000269|PubMed:12859407,
FT                                ECO:0000269|PubMed:21048046,
FT                                ECO:0000269|PubMed:23467411}.
FT                                /FTId=VAR_070413.
FT   VARIANT     332    332       G -> A (in VP; abolishes activity;
FT                                impairs protein folding and/or
FT                                stability). {ECO:0000269|PubMed:18570668,
FT                                ECO:0000269|PubMed:21048046,
FT                                ECO:0000269|PubMed:23430901}.
FT                                /FTId=VAR_070414.
FT   VARIANT     335    335       V -> G (in VP; strongly decreases enzyme
FT                                activity; impairs protein folding and/or
FT                                stability). {ECO:0000269|PubMed:10486317,
FT                                ECO:0000269|PubMed:21048046,
FT                                ECO:0000269|PubMed:23467411}.
FT                                /FTId=VAR_070415.
FT   VARIANT     348    348       Y -> C (in VP; results in enzyme activity
FT                                decrease; impairs protein folding and/or
FT                                stability; more resistant to thermal
FT                                denaturation than wild-type enzyme).
FT                                {ECO:0000269|PubMed:10870850,
FT                                ECO:0000269|PubMed:12922165,
FT                                ECO:0000269|PubMed:21048046}.
FT                                /FTId=VAR_070416.
FT   VARIANT     349    349       D -> A (in VP; decreases enzyme activity;
FT                                dbSNP:rs28936676).
FT                                {ECO:0000269|PubMed:21048046,
FT                                ECO:0000269|PubMed:23467411,
FT                                ECO:0000269|PubMed:9811936}.
FT                                /FTId=VAR_070417.
FT   VARIANT     350    350       S -> P (in VP; abolishes activity;
FT                                impairs protein folding and/or
FT                                stability). {ECO:0000269|PubMed:10486317,
FT                                ECO:0000269|PubMed:21048046}.
FT                                /FTId=VAR_070418.
FT   VARIANT     358    358       G -> R (in VP; strongly decreases enzyme
FT                                activity; impairs protein folding and/or
FT                                stability; dbSNP:rs374936130).
FT                                {ECO:0000269|PubMed:21048046,
FT                                ECO:0000269|PubMed:9811936}.
FT                                /FTId=VAR_070419.
FT   VARIANT     397    397       A -> D (in VP; strongly decreases enzyme
FT                                activity; impairs protein folding and/or
FT                                stability; dbSNP:rs141274934).
FT                                {ECO:0000269|PubMed:19320019,
FT                                ECO:0000269|PubMed:21048046}.
FT                                /FTId=VAR_070420.
FT   VARIANT     401    401       L -> F (in VP; strongly decreases enzyme
FT                                activity; dbSNP:rs776530007).
FT                                {ECO:0000269|PubMed:11474578,
FT                                ECO:0000269|PubMed:21048046,
FT                                ECO:0000269|PubMed:23467411}.
FT                                /FTId=VAR_070421.
FT   VARIANT     420    420       P -> R (in VP).
FT                                {ECO:0000269|PubMed:24073655}.
FT                                /FTId=VAR_070422.
FT   VARIANT     422    422       Y -> C (in VP; decreases enzyme
FT                                activity). {ECO:0000269|PubMed:23430901}.
FT                                /FTId=VAR_070423.
FT   VARIANT     433    433       A -> P (in VP; decreases enzyme activity;
FT                                impairs protein folding and/or
FT                                stability). {ECO:0000269|PubMed:21048046,
FT                                ECO:0000269|PubMed:9811936}.
FT                                /FTId=VAR_070424.
FT   VARIANT     444    444       L -> P (in VP; strongly decreases enzyme
FT                                activity). {ECO:0000269|PubMed:10486317,
FT                                ECO:0000269|PubMed:21048046}.
FT                                /FTId=VAR_070425.
FT   VARIANT     448    448       G -> R (in VP; abolishes enzyme activity;
FT                                impairs protein folding and/or
FT                                stability). {ECO:0000269|PubMed:11074242,
FT                                ECO:0000269|PubMed:21048046}.
FT                                /FTId=VAR_070426.
FT   VARIANT     450    450       S -> P (in VP; strongly decreases enzyme
FT                                activity). {ECO:0000269|PubMed:21048046,
FT                                ECO:0000269|PubMed:9541112}.
FT                                /FTId=VAR_070427.
FT   VARIANT     453    453       G -> R (in VP; strongly decreases enzyme
FT                                activity). {ECO:0000269|PubMed:10486317,
FT                                ECO:0000269|PubMed:21048046,
FT                                ECO:0000269|PubMed:23467411}.
FT                                /FTId=VAR_070428.
FT   VARIANT     453    453       G -> V (in VP).
FT                                {ECO:0000269|PubMed:10486317}.
FT                                /FTId=VAR_070429.
FT   MUTAGEN      59     59       R->G: Decreases enzyme activity by 75%.
FT                                {ECO:0000269|PubMed:23467411}.
FT   MUTAGEN      59     59       R->Q: Decreases enzyme activity by 90%.
FT                                Strongly decreases affinity for
FT                                protoporphyrinogen-IX.
FT                                {ECO:0000269|PubMed:23467411}.
FT   MUTAGEN      74     74       L->P: Abolishes enzyme activity. Impairs
FT                                protein folding and/or stability.
FT                                {ECO:0000269|PubMed:21048046}.
FT   MUTAGEN      97     97       R->D: Decreases enzyme activity by 89%.
FT                                Impairs protein folding and/or stability.
FT                                {ECO:0000269|PubMed:21048046,
FT                                ECO:0000269|PubMed:23467411}.
FT   MUTAGEN     166    166       L->N: Decreases enzyme activity by 95%.
FT                                {ECO:0000269|PubMed:21048046,
FT                                ECO:0000269|PubMed:23467411}.
FT   MUTAGEN     169    169       G->A: Decreases enzyme activity by 64%.
FT                                {ECO:0000269|PubMed:21048046,
FT                                ECO:0000269|PubMed:23467411}.
FT   MUTAGEN     284    284       S->I: Decreases enzyme activity by 87%.
FT                                Impairs protein folding and/or stability.
FT                                {ECO:0000269|PubMed:21048046}.
FT   MUTAGEN     290    290       V->L: No effect on enzyme activity.
FT                                {ECO:0000269|PubMed:21048046}.
FT   MUTAGEN     331    331       F->A: Decreases enzyme activity by 50%.
FT                                {ECO:0000269|PubMed:21048046,
FT                                ECO:0000269|PubMed:23467411}.
FT   MUTAGEN     334    334       L->A: Decreases enzyme activity by 86%.
FT                                {ECO:0000269|PubMed:21048046,
FT                                ECO:0000269|PubMed:23467411}.
FT   MUTAGEN     347    347       V->A: Decreases enzyme activity by 45%.
FT                                {ECO:0000269|PubMed:21048046,
FT                                ECO:0000269|PubMed:23467411}.
FT   MUTAGEN     368    368       M->A: Decreases enzyme activity by 52%.
FT                                {ECO:0000269|PubMed:21048046,
FT                                ECO:0000269|PubMed:23467411}.
FT   STRAND        4      8       {ECO:0000244|PDB:3NKS}.
FT   HELIX        12     22       {ECO:0000244|PDB:3NKS}.
FT   STRAND       24     26       {ECO:0000244|PDB:3NKS}.
FT   STRAND       29     33       {ECO:0000244|PDB:3NKS}.
FT   STRAND       35     40       {ECO:0000244|PDB:3NKS}.
FT   STRAND       45     47       {ECO:0000244|PDB:3NKS}.
FT   STRAND       53     57       {ECO:0000244|PDB:3NKS}.
FT   STRAND       59     61       {ECO:0000244|PDB:4IVO}.
FT   HELIX        65     77       {ECO:0000244|PDB:3NKS}.
FT   HELIX        81     83       {ECO:0000244|PDB:3NKS}.
FT   STRAND       84     87       {ECO:0000244|PDB:3NKS}.
FT   HELIX        92     95       {ECO:0000244|PDB:3NKS}.
FT   STRAND       97    101       {ECO:0000244|PDB:3NKS}.
FT   STRAND      104    107       {ECO:0000244|PDB:3NKS}.
FT   HELIX       128    131       {ECO:0000244|PDB:3NKS}.
FT   TURN        132    135       {ECO:0000244|PDB:3NKS}.
FT   HELIX       146    154       {ECO:0000244|PDB:3NKS}.
FT   HELIX       156    161       {ECO:0000244|PDB:3NKS}.
FT   HELIX       163    171       {ECO:0000244|PDB:3NKS}.
FT   TURN        175    177       {ECO:0000244|PDB:3NKS}.
FT   HELIX       180    183       {ECO:0000244|PDB:3NKS}.
FT   HELIX       185    194       {ECO:0000244|PDB:3NKS}.
FT   HELIX       197    203       {ECO:0000244|PDB:3NKS}.
FT   HELIX       214    221       {ECO:0000244|PDB:3NKS}.
FT   STRAND      225    229       {ECO:0000244|PDB:3NKS}.
FT   HELIX       235    246       {ECO:0000244|PDB:3NKS}.
FT   STRAND      250    252       {ECO:0000244|PDB:3NKS}.
FT   STRAND      259    262       {ECO:0000244|PDB:3NKS}.
FT   HELIX       264    266       {ECO:0000244|PDB:3NKS}.
FT   STRAND      268    271       {ECO:0000244|PDB:3NKS}.
FT   STRAND      276    284       {ECO:0000244|PDB:3NKS}.
FT   HELIX       288    294       {ECO:0000244|PDB:3NKS}.
FT   HELIX       297    299       {ECO:0000244|PDB:3NKS}.
FT   HELIX       300    307       {ECO:0000244|PDB:3NKS}.
FT   STRAND      311    321       {ECO:0000244|PDB:3NKS}.
FT   STRAND      330    334       {ECO:0000244|PDB:3NKS}.
FT   TURN        337    339       {ECO:0000244|PDB:3NKS}.
FT   STRAND      341    347       {ECO:0000244|PDB:3NKS}.
FT   HELIX       349    352       {ECO:0000244|PDB:3NKS}.
FT   HELIX       354    356       {ECO:0000244|PDB:3NKS}.
FT   TURN        358    361       {ECO:0000244|PDB:3NKS}.
FT   STRAND      363    369       {ECO:0000244|PDB:3NKS}.
FT   HELIX       371    379       {ECO:0000244|PDB:3NKS}.
FT   HELIX       386    401       {ECO:0000244|PDB:3NKS}.
FT   STRAND      408    420       {ECO:0000244|PDB:3NKS}.
FT   HELIX       426    439       {ECO:0000244|PDB:3NKS}.
FT   STRAND      443    446       {ECO:0000244|PDB:3NKS}.
FT   TURN        449    451       {ECO:0000244|PDB:3NKS}.
FT   HELIX       456    472       {ECO:0000244|PDB:3NKS}.
SQ   SEQUENCE   477 AA;  50765 MW;  2444DEAC2E6C33EE CRC64;
     MGRTVVVLGG GISGLAASYH LSRAPCPPKV VLVESSERLG GWIRSVRGPN GAIFELGPRG
     IRPAGALGAR TLLLVSELGL DSEVLPVRGD HPAAQNRFLY VGGALHALPT GLRGLLRPSP
     PFSKPLFWAG LRELTKPRGK EPDETVHSFA QRRLGPEVAS LAMDSLCRGV FAGNSRELSI
     RSCFPSLFQA EQTHRSILLG LLLGAGRTPQ PDSALIRQAL AERWSQWSLR GGLEMLPQAL
     ETHLTSRGVS VLRGQPVCGL SLQAEGRWKV SLRDSSLEAD HVISAIPASV LSELLPAEAA
     PLARALSAIT AVSVAVVNLQ YQGAHLPVQG FGHLVPSSED PGVLGIVYDS VAFPEQDGSP
     PGLRVTVMLG GSWLQTLEAS GCVLSQELFQ QRAQEAAATQ LGLKEMPSHC LVHLHKNCIP
     QYTLGHWQKL ESARQFLTAH RLPLTLAGAS YEGVAVNDCI ESGRQAAVSV LGTEPNS
//
